QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Presents Clinical Data from Ongoing Bria-IMT Trial at SABCS
Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently presented data from its ongoing trial during the San Antonio Breast Cancer Symposium (“SABCS”), one of the largest breast cancer conferences in the world. An article discussing the company reads, “The December 6 conference poster session presentation showed safety and efficacy results of BriaCell’s phase I/IIa targeted immunotherapy trial in patients with advanced breast cancer, as well as the early safety data of the combination study of Bria-IMT™ with KEYTRUDA®. KEYTRUDA® targets protein PD-1, which can block immune system cells from fighting off tumor cells. KEYTRUDA® attempts to “release the brakes”…